Biohaven’s migraine drug NURTEC™ ODT receives FDA approval
Category: #health  By Pankaj Singh  Date: 2020-02-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biohaven’s migraine drug NURTEC™ ODT receives FDA approval

A clinical-stage biopharmaceutical company, Biohaven Pharmaceutical Holding Company Ltd. recently announced that the FDA has approved NURTEC™ ODT, which has been developed for the acute treatment of migraine in adults. The drug is the first FDA approved product of Biohaven, which is focused upon advancing innovative therapies for neurological diseases.

Consumption of a quick-dissolving NURTEC ODT (rimegepant) tablet can provide fast pain relief and aid patients to function normally within an hour. The drug delivers prolonged efficacy that lasts up to 48 hours for most of the patients. However, rimegepant is not meant for the preventive treatment of migraine. Biohaven is expecting favorable results from its prevention of migraine trial in the coming months.

Vlad Coric, M.D. and CEO of Biohaven Pharmaceutical Holding was reportedly quoted saying that the approval of NURTEC ODT by FDA marks an important milestone for the migraine community and is also a transformative event for the company. Millions of people who are suffering from migraine are not satisfied with their current acute treatment because of the significant tradeoffs; reduced ability to function and troublesome side effects.

NURTEC ODT can be considered an important novel oral acute treatment for migraine that has the potential to instantly reduce and eliminate pain as well as aid patients to get back to their lives normally.

Coric added saying that NURTEC ODT will be the first of many innovative medicines created by the company to become available to treat dreadful neurological diseases, a therapeutic category many other companies have neglected. He further added that Biohaven is dedicated to helping patients with such conditions, who often have limited/no treatment options, to live better and more productive lives.

With quick-dissolve oral tablet formula, NURTEC ODT works by blocking CGRP receptors (a G-protein-coupled receptor of the B subtype), thereby treating the roots of migraine. The drug is not narcotic or opioid, does not have addiction potential and is not scheduled as a controlled substance by the United States Drug Enforcement Administration.  

Source Credit: https://www.prnewswire.com/news-releases/biohavens-nurtec-odt-rimegepant-receives-fda-approval-for-the-acute-treatment-of-migraine-in-adults-301013021.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.